Abstract: Some embodiments of the present disclosure present methods and systems for remotely capturing an image of an eye of a user via a user interface bidirectionally linked to a remote server that is configured to anonymize data communicated from the user device. In some embodiments, a user device may activate its camera after receiving a request at the user interface from the remote server. Further, the user interface may determine a zoom level for the camera based on a pre-set zoom level corresponding to the type of the user device, wherein the pre-set zoom level corresponding to the non-portable user device is greater than the pre-set zoom level corresponding to the portable user device; and capture the image based on the determined zoom level. In some instances, the user device may transmit the data including the captured image to the remote server via an encrypted bi-directional communication link.

Abstract: Some embodiments of the present disclosure present methods and systems for remotely capturing an image of an eye of a user via a user interface bidirectionally linked to a remote server that is configured to anonymize data communicated from the user device. In some embodiments, a user device may activate its camera after receiving a request at the user interface from the remote server. Further, the user interface may determine a zoom level for the camera to capture the image of the eye of the user facing the camera and capture the image based on the determined zoom level. In some instances, the user device may transmit the data including the captured image to the remote server via an encrypted bi-directional communication link.

Abstract: Provided herein are formulations and compositions for ocular diseases or disorders such as dry eye disease. Further provided herein are methods for manufacturing ocular formulations and compositions.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.

Abstract: Methods and kits for improving tear production are described, along with topical pharmaceutical compositions. In certain instances, the composition comprises pentoxifylline and a pharmaceutically acceptable carrier. The compositions also may further comprise another active agent, such as an anti-bacterial agent, antiviral agent, antifungal agent, or immunosuppressant agent, and combinations thereof.

Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Abstract: Methods and kits for improving tear production are described, along with topical pharmaceutical compositions. In certain instances the composition comprises pentoxifylline and a pharmaceutically acceptable carrier. The compositions also may further comprise another active agent, such as an anti-bacterial agent, antiviral agent, antifungal agent, or immunosuppressant agent, and combinations thereof.

Abstract: Pharmaceutical compositions that include aqueous suspensions of a therapeutically effective quantity of a diaminopyrimidine compound (such as pyrimethamine) are provided herein. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions and methods for preventing, treating, or alleviating cytokine release syndrome are described, the compositions comprising pentoxifylline and a pharmaceutically acceptable carrier. Methods for using such compositions are also described.

Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.

Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.